Endocrine Abstracts

Diaserein is used in the spesific and long-term treatment of degenerative joint diseases (as osteoarthritis). In vitro studies have showed that Diaserein and its active metabolyte Rheinin inhibate production and activity of interleukin-113 (IL-113), some proinflamatuar and pro-catabolic cytokines. Interleukin-113 play important role to trigger production of more pro-inflamatuar factors as cytokines, cyclo-oxygeneas, prostogalandines, nitric oxide, matrix metalloproteinases in chondrocyte degradation, snobial enflamation, remodelling of subchondral bone. Diaserein stimulates Transformic Growth Factor 13 (TGF-13) even if IL-113 exists. Diaserein stimulates synthesis of chondral matrix components as proteoglicans, glicoseaminoglicans, hyaluronic asids. After all Diaserein decreases the lost of chondral components continuously. We present 41 case series of patients that is used Diaserein on the treatment of osteoarthritis in various joints (gonarthroisis, coxarthritis, dejenerative lomber diseases). 41 patients have followed up clinically in 2014–2016. 17 patients in this serie have show intolerance to medicine by diarrhea, vomitting and some clinical compliants. At the research of these intolareted patients 16 patients have glucose intolerance as Diabetes Mellitus Type 1 and 2. At the researching of literature, Diaserein were not advised severe renal insufficiency, gastrointestinal disorder (Chrone, Ulserative Colit…), hepatic insufficiency and also glucose intolerance. Diaserein must be used carefully on the patients that have renal and hepatic insufficiency and failure. And also it must not be preferred on the patients which have glucose intolerance because of seein severe side effects.